![PDF) Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD | Giovanni Latella and Giorgos Bamias - Academia.edu PDF) Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD | Giovanni Latella and Giorgos Bamias - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/42047691/mini_magick20190218-10644-oh6d1.png?1550497188)
PDF) Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD | Giovanni Latella and Giorgos Bamias - Academia.edu
N029 Patients experience of advice received on the use of topical therapies in inflammatory bowel disease (IBD) N030 Real benefi
![Figure 1 | Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review | SpringerLink Figure 1 | Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review | SpringerLink](https://media.springernature.com/full/springer-static/image/art%3A10.1007%2Fs12325-019-00998-3/MediaObjects/12325_2019_998_Fig1_HTML.png)
Figure 1 | Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review | SpringerLink
N-ECCO survey results of nursing practice in caring for patients with Crohn's disease or ulcerative colitis in Europe
![Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD - [PDF Document] Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD - [PDF Document]](https://demo.fdocuments.in/img/742x1000/reader018/reader/2019122101/575097c31a28abbf6bd64878/r-1.jpg?t=1598473121)
Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD - [PDF Document]
![PDF) P698 Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn's disease and ulcerative colitis patients PDF) P698 Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn's disease and ulcerative colitis patients](https://i1.rgstatic.net/publication/330650184_P698_Persistence_clinical_effectiveness_and_safety_of_vedolizumab_in_the_post-marketing_real_clinical_practice_in_Italy_a_double-centre_2-year_experience_in_Crohn's_disease_and_ulcerative_colitis_pati/links/5e9f0a7692851c2f52b796be/largepreview.png)
PDF) P698 Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn's disease and ulcerative colitis patients
![East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.](https://www.hirsla.lsh.is/bitstream/handle/2336/325171/Gut-2014-Burisch-588-97.pdf.jpg?sequence=6&isAllowed=y)